title: [Plasmapheresis, a safe treatment when applied to the correct indication and with awareness of the complications].
abstract: Plasmapheresis is an extracorporeal technique used to remove pathogenic macromolecules from the circulation, particularly autoantibodies. This is illustrated in 2 female patients. The first patient, aged 61 years, was treated successfully with non-selective plasmapheresis for acute humoral rejection shortly after receiving a renal allograft. In the second patient, aged 82 years, plasmapheresis for refractory myasthenia gravis had to be stopped because of bradycardia and hypotension during the procedure. She was treated successfully with immunoglobulins. Plasmapheresis is used to treat neurological, renal, haematological and systemic disorders. In nonselective plasmapheresis, the plasma is replaced with saline and albumin or donor plasma. In selective plasmapheresis a highly selective filter is used to remove a specific, pathogenic macromolecule. Adverse effects of the treatment include disturbances of the acid-base equilibrium or the coagulation, and allergic reactions. Most of these complications, however, can nowadays be avoided.
authors.affiliation: Centre Hospitalier Universitaire Vaudois, Service de Néphrologie et Consultations d'Hypertension, Département de Médecine, Rue du Bugnon 17, 1011 Lausanne, Zwitserland. mennopruijm@hotmail.com
authors.forename: M T
authors.initials: MT
authors.lastname: Pruijm
authors.forename: B
authors.initials: B
authors.lastname: Vogt
authors.forename: A
authors.initials: A
authors.lastname: Cherpillod
authors.forename: M
authors.initials: M
authors.lastname: Burnier
mesh_terms: D000369:Aged, 80 and over; D000906:Antibodies / Q000097:blood; D000917:Antibody Formation / Q000502:physiology; D005260:Female; D006084:Graft Rejection / Q000276:immunology / Q000628:therapy*; D006706:Homeostasis; D006801:Humans; D016756:Immunoglobulins, Intravenous; D016030:Kidney Transplantation / Q000009:adverse effects; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000628:therapy*; D010956:Plasmapheresis / Q000379:methods*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000906:Antibodies; D016756:Immunoglobulins, Intravenous